<img src="https://ml.globenewswire.com/Resource/Download/9cd3169e-5a07-44f7-b820-b6f4fff6e4d1?size=2" nborder="0" align="left" hspace="5" vspace="5" title="Caribou_logo.png" alt="Caribou Biosciences, Inc."/>BERKELEY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=zw4HaCv2dsVUzxLE3PCzYiiQJYH7Wlo--olEzUgFf4onHmauJaCZa2dD_oImGYJznZPxWJfDLAxvt328eSOy0_xRTxuqvPNhtST2F0yUTXI=" rel="nofollow" target="_blank" title="Caribou Biosciences">Caribou Biosciences</a>, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Caribou’s management team will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, at 12:30pm ET in New York, New York. For more information and a link to the <a href="https://www.globenewswire.com/Tracker?data=mcPRdDyqQt5t-oXjQoCB-jERLer7nqmuryDBcVJZe50UqxywzCwvqQaP3_4fVc7IMpMbSqvq8TEqdBhtm4vIOST9lHMUhNAQjaCW2OO94jCpbQYwG8xOoNnxhh_BASjBXizi3h8KDGm1ZBH7Cek7hA==" rel="nofollow" target="_blank" title="webcast">webcast</a>, visit the <a href="https://www.globenewswire.com/Tracker?data=0Gp6BoTCu5vEKZoQv7O8zkZxDCIBB4SIDEaqT7bbmisx9mT146thydmG0hyXzhxaLhiz8qHmPnWtzz8rxUkfCSuILQ9dnevH3rr6NkEWH4JBH-KOfbo6In3ndYXFu44n" rel="nofollow" target="_blank" title="Events">Events</a> page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event. About Caribou Biosciences, Inc. Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Caribou’s chRDNA genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Follow the company @CaribouBio and visit <a href="https://www.globenewswire.com/Tracker?data=eE19chimMEjQOketTK9uTk8Cueyk_HpWURa13yUIg2105K4mcZT8ayLxE4ERxaCdSNbHR3Vmc3zRYfCxi8B-DYTX3tylVKOJyp29A6nPwUo=" rel="nofollow" target="_blank" title="www.cariboubio.com">www.cariboubio.com</a>. Caribou Biosciences, Inc. contact: Peggy Vorwald, PhD investor.relations@cariboubio.com media@cariboubio.com <img alt="" src='https://ml.globenewswire.com/media/YmU3ZGU2NDgtYzBlNS00NGViLWI4MTQtNzE2YzkxMzEwMjY0LTEyMjEwNzYtMjAyNi0wNS0xMy1lbg==/tiny/Caribou-Biosciences-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn